Bradyphrenia, or slowed thinking, is a common symptom of many brain disorders, including Parkinson's disease and some forms of schizophrenia, which can cause slow reaction times and fatigue. Patients may describe slowed thinking processes, along with prolonged reaction times, severe memory impairment, and poor motor control. From ancient Greek, "bradyphrenia" means "slow thinking."
Nearly half of hospitalized Parkinson's patients show signs of Bradyphrenia, according to Steck's research. Many neuroscientists believe that this state is an additional feature of Parkinson's disease. A 1966 study by Wilson et al. found that patients with Parkinson's disease had significantly increased information latency. This theory has been further confirmed in several studies of people with Parkinson's disease.
However, not all people with Parkinson's disease have this condition, and some neuroscientists have suggested that bradyphrenia can exist independently of Parkinson's disease.
Researcher Rogers and others found that bradyphrenia and a state called "psychomotor retardation" behave similarly in patients with Parkinson's disease. Psychomotor retardation is often considered one of the hallmarks of major depression. The researchers examined people with Parkinson's disease and those with depression who participated in a series of tasks that required rapid reactions.
People with Parkinson's disease had longer reaction times on these tasks, while people with depression showed improvements.
In addition to Parkinson's disease, patients with Alzheimer's disease and depression often exhibit features of Bradyphrenia. Pate and Margolin's research shows that the slowed thinking speed of Alzheimer's patients is related to damage to the cerebral cortex. In people with depression, evidence of bradyphrenia is only apparent if there is past neurological damage.
In drug addiction research, expert Martin and others found that bradyphrenia is regarded as one of the earliest signs of overdose of opiates (such as heroin). Their investigation mentioned that the presence of bradyphrenia is usually seen as an early stage of symptoms. It is worth noting that this symptom may indicate that the patient will have more serious problems later.
A 63-year-old man was readmitted to the hospital after exhibiting symptoms of bradyphrenia, including decreased concentration and poor memory.
At present, there are no specific drugs that directly improve the thinking speed of patients with Bradyphrenia, and most treatments are based on Parkinson's disease therapies. The researchers suggest that steroid therapy or a combination of L-DOPA and carbidopa may be used to improve symptoms of bradyphrenia.
Despite short-term benefits, long-term use of L-DOPA may actually slow cognitive speed.
Bradyphrenia was first described by French neurologist Naville during the paralytic encephalitis epidemic in the early 20th century. At the time, he observed mental and behavioral slowing in patients, symptoms that marked progressive brain damage.
Understanding and research on Bradyphrenia continues. As the scientific community gains a deeper understanding of the mechanisms behind it, treatments and their effectiveness are expected to be further improved.
Have you ever thought that this seemingly minor symptom may indicate a deeper health problem?